CDSCO Panel Recommends Approval for Vorasidenib with Phase-III Waiver, Mandates Phase-IV Trial in India
New Delhi: In response to a proposal by Servier India Pvt. Ltd. seeking approval to import and market the anti-cancer drug Vorasidenib Tablets 10 mg and 40 mg, the Subject Expert Committee (SEC) on Oncology under the Central Drugs Standard Control Organization (CDSCO) has recommended the grant of marketing permission with a waiver of local Phase-III clinical trials, subject to post-marketing commitments.
The proposal was reviewed during the SEC meeting held on 17th July 2025, where the company sought approval for the drug along with exemption from conducting local Phase-III clinical trials. The committee noted that Vorasidenib has already been granted orphan drug status in other countries, and that the prescribing information for the Indian product was in line with regulatory approvals abroad.
Vorasidenib is a dual isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, indicated for the treatment of adult and pediatric patients (aged 12 years and older) with Grade 2 astrocytoma or oligodendroglioma harboring IDH1 or IDH2 mutations, following surgery including biopsy, subtotal resection, or gross total resection.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.